Recommendation: ACCUMULATE · Rating 7.3/10
The CLIN11 investment thesis rests on three pillars: (i) credit quality — a 100% current portfolio across 31 CRIs with robust real estate collateral, originated by a boutique (Clave) now housed within BTG Asset; (ii) attractive carry — an average spread of IPCA+10.3% (high for high-grade), with a 12m DY of ~12.6% exempt from income tax for individual investors; and (iii) discount to NAV — units trading at R$ 92.04 versus a book value of R$ 98.69 (P/BV 0.93), offering a margin of safety in a fund with reputable management.
The counterpoint is market-related rather than credit-related: with 97% of the portfolio indexed to IPCA+ and carrying meaningful duration (27% above 4 years), book value is sensitive to the real interest rate curve—the historical drop to R$ 72.60 was purely mark-to-market, with zero defaults. This is accompanied by a slight decline in DPU (from R$ 1.15 to R$ 0.95 in line with Selic) and a 20% performance fee on benchmark excess. For income investors with a long-term horizon and tolerance for mark-to-market volatility, CLIN11 delivers quality real estate credit at a competitive premium.
Our current reading of CLIN11 is ACCUMULATE, with a score of 7.3/10. This score comes neither from the manager nor the administrator: it is Rico aos Poucos' editorial assessment, built from the documents the fund files with the CVM. Below is what supports it — and what argues against it.
3rd out of 17. Clave/BTG portfolio with zero defaults since inception, tax-exempt DPU yield of ~13.4%, and a ~15% discount to book value. It ranks below Pátria peers due to a declining DPU (R$ 1.15→0.95), a 20% performance fee, and meaningful duration (35% above 2 years) that exposes the fund to mark-to-market volatility. Even so, it is a solid high-grade fund, ranking among the best in its bucket.
Safety in a REIT is not yes or no — it is how much risk you accept. CLIN11 has a medio risk profile. What that means in practice:
| Component | Level |
|---|---|
| Concentração | 2.5 |
| Price volatility | 3.5 |
| Dividend volatility | 2.5 |
| Liquidez | 2.0 |
| Underlying asset risk (credit) | 2.0 |
| Financial/governance risk | 1.5 |
A 97% allocation to IPCA+ concentrates risk in the real interest rate curve. During a sharp expansion of NTN-B yields (such as in 2024), unit prices fall due to mark-to-market adjustments even with the portfolio intact — which drove the unit price down to R$ 72.60.
27% of the portfolio matures beyond 4 years, and certain holdings feature a duration of 6.9 years (XPLG). The longer the duration, the higher the book unit price volatility with each movement in real interest rates.
The 20% performance fee on returns exceeding 100% of IPCA + IMA-B5 Yield reduces payouts in years of strong performance. Unitholders should track how much the net delivery outperforms the benchmark.
35% allocated to residential real estate with developers (MRV, Tenda, Direcional, Metrocasa, Diálogo). Although fragmented and well-collateralized, a prolonged high-interest-rate cycle could increase contract cancellations in the underlying portfolios.
The average IPCA+ 10.3% spread is high for high-grade credit — part of it comes from higher-yielding names (Metrocasa, GD Elleven, Tradimaq, Tenda Pré-Chaves). Being 'current today' does not eliminate the structural risk of these debtors.
| Scenario | Description |
|---|---|
| favoravel | Selic/NTN-B yields declining in 2026-2027. Long duration generates positive mark-to-market gains, and the unit price recovers to R$ 96-100 (P/BV ~1.0). Nominal DPU drops slightly, but capital gains drive total return. |
| favoravel | Yield curve remains stable, portfolio continues to be current. Investors capture an IPCA+ 10.3% carry and a tax-exempt DY of ~12.6%. Unit price moves sideways at R$ 90-95. A pure income scenario. |
| desfavoravel | Fiscal risk and inflation push NTN-B yields upward. Negative mark-to-market adjustments drive the unit price down to R$ 82-88. The portfolio remains current — losses occur only if sold at the bottom of the movement. |
| desfavoravel | Delinquency or default in one of the top 5 names (interest-sensitive residential) forces a stop accrual and a DPU adjustment to R$ 0.85-0.90. Hard collateral limits losses, but unit prices decline. |
CLIN11 (Clave Índices de Preços FII) closed April/2026 with net assets of R$ 429.0 million, 4,346,763 units, 10,732 unitholders, and 85.9% of its assets allocated across 31 CRI operations — all current — with 14.3% in cash/fixed income (Tesouro Selic and repurchase agreements). The portfolio is 97% indexed to IPCA+ with an average spread of IPCA+ 10.3% (high for high-grade credit) and diversified across residential (35%), corporate real estate (17%), retail (16%), logistics (15%), office (6%), and others, featuring debtors such as Diálogo, JHSF, MRV, Tenda, Direcional, XPLG, HGRU11, Souza Cruz/BAT, Pátio Malzoni, and São Carlos. The DPU is R$ 0.95/unit (12m DY ~12.6%, tax-exempt for individual investors) and April/26 cash earnings (R$ 1.17/unit) comfortably cover the distribution.
CLIN11's primary differentiator is institutional and credit quality. Management originated at Clave Alternativos, a boutique specialized in real estate credit, and was integrated into BTG Pactual Asset Management in 2025 — preserving the team and mandate while adding the balance sheet, origination, and governance of one of Latin America's largest banks. The portfolio has never recorded a default: operations feature robust hard collateral (subordinations of 15% to 60%, property fiduciary liens with controlled LTVs, reserve funds, and repurchase obligations). Fund risk is essentially market-driven rather than default-driven: with 97% allocated to IPCA+ and significant duration (27% above 4 years), book unit values fluctuate with the real interest rate curve — it was the expansion of NTN-B yields, rather than credit events, that drove unit prices down from ~R$ 100 to R$ 72.60 in Dec/2024.
Looking ahead, the investment thesis rests on quality carry with optionality for capital gains. In a yield curve compression scenario (Selic/NTN-B yields declining in 2026-2027), long duration generates positive mark-to-market gains, and unit prices tend to converge from the current 0.93 P/BV toward book value, combining with a ~10% real carry for an attractive total return. In a stability scenario, investors capture a tax-exempt DY of ~12.6% with a current portfolio. Key headwinds include mark-to-market volatility (investors who must sell during yield curve expansions realize losses), a slight downward trend in DPU tracking interest rates (from R$ 1.15 to R$ 0.95), and a 20% performance fee on returns exceeding IPCA + IMA-B5 Yield. For income investors with a long-term horizon and tolerance for unit price fluctuations, CLIN11 is one of the most solid high-grade IPCA+ paper fund options in the market. Rating 7.3/10 (BUY) reflects the combination of top-tier management, a current portfolio, competitive carry, and a discount to book value.
Current recommendation: ACCUMULATE. Rating 7.3/10. CLIN11 lends money for real estate developments — via CRIs (debt securities backed by real estate) — and distributes the interest monthly, exempt from income tax for individual investors. The portfolio contains 31 operations, all current on payments (zero delinquency), yielding…
Our current read on CLIN11 is “ACCUMULATE”. Rating 7.3/10. Assess it against your risk profile and the points of attention listed above.
The main points of attention for Clave Índices de Preços FII include: Significant duration — mark-to-market exposure; DPU in a downward trend — from R$ 1.15 to R$ 0.95; 20% performance fee over benchmark excess; Concentration in the top 5 assets (~30% of NAV).
CLIN11 is suitable for: Investors seeking tax-exempt monthly income (for individuals) in high-grade real estate credit with a proven current portfolio Profiles wanting real interest rate exposure (IPCA+) with an IPCA+10.3% carry who accept mark-to-market volatility Those who value reputable management (Clave/BTG Asset) and diversification across 31…